Orange Book Patent Flags, Use Codes, and ANDA Context
Audit the structural fields of US FDA Orange Book patent listings—Drug Substance (DS) flags, Drug Product (DP) flags, Patent Use Codes (U-codes) and delist requests—and the matching FDA Paragraph IV certification records, using the pinned September 2026 incretin capture. NDA209637 carries three Paragraph IV entries in this capture. Understanding what each field represents is essential for reading Hatch-Waxman source records accurately.
Uses the shipped September 2026 FDA capture, opened on NDA209637, to examine DS/DP flags, method-of-use codes and the Paragraph IV certification list (three entries on this application; the Orange Book capture holds no approved generic rows for it yet).
Read Drug Substance (DS), Drug Product (DP), and Use-Code columns accurately
Every row in the FDA Orange Book `Patent.txt` file links an NDA number and three-digit product number to a USPTO patent number, an expiration date, and three structural classification columns: `Drug_Substance_Flag`, `Drug_Product_Flag`, and `Patent_Use_Code`. A single patent can carry `Y` in the DS column (claiming the active pharmaceutical ingredient), `Y` in the DP column (claiming the pharmaceutical formulation or drug-device presentation), a `U-####` identifier in the use-code column (claiming a specific approved method of treatment), or a combination of all three.
Distinguishing these three columns is fundamental when reading a listed-patent landscape. A patent flagged `DS = Y` typically expires earlier in a product’s lifecycle than later-filed formulation (`DP = Y`) or method-of-use (`U-####`) patents. Moreover, when a patent carries only a method-of-use code and neither DS nor DP is flagged, its listing scope is tied specifically to the labeled indication described by that use code.
Keep FDA ministerial listings distinct from claim scope and litigation records
The FDA’s role in maintaining the Orange Book patent register is ministerial: the agency publishes the patent numbers, expiration dates, DS/DP flags, and use-code narratives certified by the NDA sponsor on Form FDA 3542 without conducting an independent patent-claim examination. A `Patent_Delist_Request_Flag` indicates whether the sponsor has requested delisting of a challenged patent under statutory procedures.
When inspecting NDA209637 and related incretin records in the workspace, examine both unique patent numbers and product-specific coverage while keeping the boundaries of the dataset explicit. Determining whether an abbreviated application infringes a listed claim, qualifies for a Section viii labeling carve-out, or triggers a 30-month regulatory stay requires consulting the patent specification, prosecution history, and court records alongside qualified legal counsel.
Equations and variables
Listed patent classification tuple per (Application, Product, Patent)
Category(row) = (DS_Flag ∈ {Y, N}, DP_Flag ∈ {Y, N}, Use_Code ∈ {U-####, ∅})
- DS_Flag
- Sponsor declaration that the patent claims the active drug substance (active ingredient)
- DP_Flag
- Sponsor declaration that the patent claims the formulated drug product or delivery device
- Use_Code
- Code identifying an approved method of using the drug product claimed by the patent
Distinct patent count vs distinct listing-row count on an application
Nunique-patents ≤ Nlisting-rows (one patent listed across multiple product strengths or *PED rows)
- Nunique-patents
- Number of distinct USPTO patent numbers associated with the NDA
- Nlisting-rows
- Total rows in Patent.txt across all product numbers and pediatric attachments
Scope and limitations
- Orange Book DS, DP, and Use Code fields are submitted by the NDA holder without substantive claim construction by the FDA; the FDA acts in a ministerial capacity when publishing Patent.txt.
- The Orange Book Patent.txt file lists reference-drug patents and matching ANDA product rows in Products.txt, but it does not contain district-court litigation dockets, settlement agreements, or 180-day exclusivity forfeiture rulings.
- Not legal, regulatory, medical, or investment advice; inspecting DS/DP flags and use codes is not a patent validity, infringement, or freedom-to-operate analysis.
Sources and provenance
- FDA Orange Book data filesFDA source terms; no new licence classification
Listed protection is not a claim construction or freedom-to-operate opinion.
- FDA Orange Book data files and field descriptionsFDA source terms; Patent.txt and Products.txt schema reference
- 21 CFR 314.53 submission of patent information for Orange Book listingUS government public domain; DS, DP, and method-of-use listing rules
Technical questions
What is the difference between a Drug Substance (DS), Drug Product (DP), and Method-of-Use patent in the Orange Book?
Under 21 CFR 314.53, NDA holders submit three types of patents for listing: Drug Substance (DS) patents that claim the active ingredient itself (or a polymorph/salt thereof), Drug Product (DP) patents that claim the finished formulation, tablet, or pen injector composition, and Method-of-Use patents (carrying a U-code) that claim an approved indication or dosing regimen on the product label.
Why does the same patent number appear multiple times under one NDA?
In Patent.txt, listings are indexed per product strength (Product_No 001, 002, 003, etc.), and a patent that also received a 6-month pediatric extension appears a second time with a "*PED" suffix. Counting raw table rows without deduplicating by patent number and product number artificially inflates the patent count.
Does the FDA Paragraph IV list tell you whether a challenge will succeed?
No. The FDA Paragraph IV list records that an ANDA filer has certified against a listed patent, alleging it is invalid, unenforceable or not infringed; a filer may instead use a Section viii statement to carve out a method-of-use code. Those disputes are resolved in federal court and USPTO proceedings, not by the list or the Orange Book flags.
Connected workflows
- US incretin listed-patent inspection
Open the primary US incretin listed-patent and exclusivity workspace.
- HER2 and TROP2 ADC trial-record exploration
Compare clinical trial records for oncology biologics in the pipeline workspace.
- Chemical structure and canonical SMILES
Inspect chemical structures and canonical SMILES representations of small molecules.